A preventive treatment for dementia may proceed to clinical trials after successful animal testing.
The US-led research is looking to develop effective immunotherapy via a new vaccine to remove ‘brain plaque’ and tau protein aggregates linked to Alzheimer’s disease.
Recent success in bigenic mice models supports progression to human trials in years to come, the researchers say.
A new paper in the journal Alzheimer’s Research & Therapy paves the way for more work in 2020, with medical researchers at the Institute for Molecular Medicine and University of California, Irvine (UCI) working with a successful vaccine formulated on adjuvant developed by Flinders University Professor Nikolai Petrovsky in South Australia.
The latest research aims to come up with a new treatment to remove accumulated beta-amyloid (A?) plaques and neurofibrillary tangles composed of hyperphosphorylated tau, which together lead to neurodegeneration and cognitive decline in Alzheimer’s disease.
Alzheimer’s disease (AD) is the leading cause of age-related dementia, affecting about 5.7 million people in the US. Major challenges in AD include the lack of effective treatments, reliable biomarkers, or preventive strategies.
Professor of the Institute for Molecular Medicine Anahit Ghochikyan and colleagues, Associate Professors Hvat Davtyan and Mathew Blurton-Jones from UCI, and other co-authors tested the universal MultiTEP platform-based vaccines formulated in the adjuvant developed at Professor Petrovsky’s Australian lab.
The possible new therapies were tested in bigenic mice with mix A? and tau pathologies.
“Taken together, these findings warrant further development of this dual vaccination strategy based on the MultiTEP technology for ultimate testing in human Alzheimer’s disease,” the lead authors Professor Ghochikyan and Blurton-Jones conclude.
Professor Petrovsky says the Advax adjuvant method is a pivotal system to help take the combination MultiTEP-based A?/tau vaccines therapy, as well as separate vaccines targeting these pathological molecules, to clinical trials – perhaps within two years.
“Our approach is looking to cover all bases and get past previous roadblocks in finding a therapy to slow the accumulation of A?/tau molecules and delay AD progression in a the rising number of people around the world,” says Professor Petrovsky, who will work in the US for the next three months.
Several promising drug candidates have failed in clinical trials so the search for new preventions or therapies continues.
A recent report on human monoclonal antibody, aducanumab, showed that high dose of this antibody reduced clinical decline in patients with early AD as measured by primary and secondary endpoints.
However, it is obvious that it could not be used as a preventive measure in healthy subjects due to the need for frequent (monthly) administration of high concentrations of immunotherapeutic.
Professor Ghochikyan says there is a pressing need to keep searching for new preventive vaccine to delay AD and slow down progression of this devastating disease.
The new combined vaccination approach could potentially be used to induce strong immune responses to both of the hallmark pathologies of AD in a broad population base of vaccinated subjects with high MHC (major histocompatibility complex) class II gene polymorphisms, the new paper concludes.
Go deeper with Bing News on:
- Vaccine Phase 1c: Why obese people qualify for the shots in Tennesseeon March 5, 2021 at 8:16 pm
Starting Monday, a new group of people are eligible for COVID-19 vaccines in Tennessee. Phase 1c includes anyone over age 16 with high-risk health conditions like COPD, dementia, heart failure, cystic ...
- City opens vaccine appointments for those in phase 1c, includes most Memphians with co-morbiditieson March 5, 2021 at 6:36 pm
Next week's COVID-19 vaccination appointments open Friday at noon, the city of Memphis announced in a tweet. People with co-morbidities outlined in phase 1c are eligible for vacci ...
- Doctors in Chicago are making house calls to give vulnerable patients the Covid-19 vaccineon March 5, 2021 at 5:28 pm
A new program at a Chicago hospital is helping protect people from Covid-19 by sending doctors to give vaccines to patients who are 65 and older and can't get to a clinic.
- Nashville Phase 1c vaccines given by honor systemon March 5, 2021 at 4:59 pm
Tennessee will move into Phase 1c of vaccinations for those 16 and older with high-risk health conditions Monday, but Metro Public Health says they will not be verifying these health conditions.
- New study emphasizes importance of those with dementia getting vaccinatedon March 5, 2021 at 2:48 pm
New data shows that people with dementia or Alzheimer’s disease are twice as likely to get COVID-19. The Alzheimer’s Association is now encouraging everyone to get the vaccine.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Homeless shelter set to leave San Diego Convention Center, now seen as vaccine siteon March 6, 2021 at 1:53 pm
The 11-month venture protected homeless people during pandemic and connected more than 1,000 with housing opportunities ...
- NHS calls up people aged 56-59 for Covid vaccineon March 6, 2021 at 1:29 pm
People aged between 56 and 59 are being invited to book Covid-19 vaccinations this week, NHS England has said. Hundreds of thousands of letters for the age group began landing on doorsteps on Saturday ...
- Covid-19 vaccine: Amount of people with hesitancy dropping rapidlyon March 6, 2021 at 1:19 pm
The release of Johnson & Johnson's Covid-19 vaccine and its partnership with Merck means that President Joe Biden expects the US to have enough Covid-19 vaccines delivered to cover every adult by the ...
- Covid-19: Vaccine offers for those aged 56 or overon March 6, 2021 at 1:16 pm
People aged 56 to 59 in England are being invited to book their coronavirus vaccine from this week. Letters for people in the age group, offering them the vaccine, started being delivered to homes on ...
- Fans and artists must have Covid vaccine before attending music festivals, say organiserson March 6, 2021 at 12:39 pm
Anxious promoters say government should make having a jab a condition for everyone ...